When are medical apps medical? Off-label use and the Food and Drug Administration

被引:3
|
作者
Krieger, William H. [1 ]
机构
[1] Univ Rhode Isl, Kingston, RI 02881 USA
来源
DIGITAL HEALTH | 2016年 / 2卷
关键词
Medical apps; Food and Drug Administration; mobile healthcare; off-label; conflict of interest;
D O I
10.1177/2055207616662782
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
People have a love/hate relationship with rapidly changing healthcare technology. While consumer demand for medical apps continues to grow as rapidly as does supply (there are over 100,000 health, wellness and medical applications, or 'apps' on the market), healthcare professionals and safety experts worry about the impact of these apps on the health consumer. In response to the rapidly growing mobile healthcare sector, the Food and Drug Administration has put forth guidelines to regulate 'mobile medical apps' (MMAs), those health-related apps that are (self) designated as medical devices. In this article, I argue that this decision, to only regulate apps that bill themselves as medical devices, will create a market for 'off-label' app use. Further, I will talk about the oft used analogy between off-label apps and off-label pharmaceuticals, showing that off-labeling apps will provide patients none of the benefits that come with a physician prescribing a drug off-label, while exposing the mobile healthcare consumer to significant risks that go significantly beyond those that we know of (and must accept) from prescription drugs. Recognizing that the Food and Drug Administration is not going to be able to significantly change its policies on oversight, I will suggest specific actions to at least mitigate some of the risks associated with off-label app use.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Confounding Factors In Off-Label Drug Use
    Greenberg, Paul E.
    Pike, Crystal
    Sisitsky, Tammy
    HEALTH AFFAIRS, 2012, 31 (02) : 460 - 460
  • [32] Off-label drug use in hospitalized children
    Shah, Samir S.
    Hall, Matthew
    Goodman, Denise M.
    Feuer, Pamela
    Sharma, Vidya
    Fargason, Crayton, Jr.
    Hyman, Daniel
    Jenkins, Kathy
    White, Marjorie L.
    Levy, Fiona H.
    Levin, James E.
    Bertoch, David
    Slonim, Anthony D.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (03): : 282 - 290
  • [33] Off-Label Use of Medical Devices in Radiology: Regulatory Standards and Recent Developments
    Smith, John J.
    JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2010, 7 (02) : 115 - 119
  • [34] EVALUATION AND MONITORING OF OFF-LABEL DRUG USE
    Danes, I
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 7 - 8
  • [35] Off-Label Drug Use: The Authors Reply
    Kesselheim, Aaron S.
    Darby, Devan L.
    Avorn, Jerry
    HEALTH AFFAIRS, 2012, 31 (02)
  • [36] OFF-LABEL DRUG USE IN ONCOLOGY PATIENTS
    Moreno, Kathryn
    Parks, Debra
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [37] LITERATURE PATTERN ON OFF-LABEL DRUG USE
    Mesgarpour, B.
    Mueller, M.
    Herkner, H.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 145 - 145
  • [38] Automated Detection of Off-Label Drug Use
    Jung, Kenneth
    LePendu, Paea
    Chen, William S.
    Iyer, Srinivasan V.
    Readhead, Ben
    Dudley, Joel T.
    Shah, Nigam H.
    PLOS ONE, 2014, 9 (02):
  • [40] Off-Label Drug Use in Pediatric Patients
    Kimland, E.
    Odlind, V.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (05) : 796 - 801